Norcliffe Capital

Norcliffe draws on CSO David Onions' extensive academic and commercial network — spanning virology research leadership at the University of Glasgow and senior roles at multiple biotech firms — to identify early-stage UK life-science companies with strong IP. The firm vets a maximum of four investments per year, focusing on medtech and biotech innovations that meet its specific mandate for a growing global market, a 3-10x return target, and a disruptive technology thesis (per the firm's published investment mandate).

Norcliffe does not operate a pooled fund. Each investment is structured as a standalone EIS or SEIS-qualifying round, allowing high-net-worth individuals to invest directly into a specific private company. The firm acts as a placement agent and post-investment manager rather than a blind-pool fund manager, with each raise having a discrete deadline and minimum (per the firm's current open rounds).

Norcliffe targets UK-based medtech and biotech companies with strong global IP, a management team ready for investment, a clearly defined consumer need, and a target exit within 4–7 years. Each candidate must target a 3-10x return, operate in a growing global market, and show a disruptive technology that either fulfills unmet needs or replaces older methods (per the firm's published mandate).

Founder and CEO Patricia Reynolds leads the firm, bringing 15 years of RBS corporate finance experience and over a decade in EIS equity fundraising. CSO David Onions, a former Professor of Veterinary Pathology and Director of the Leukaemia Research Fund's Human Virus Centre, leads scientific evaluation. Investment decisions are made by this small, principal-led team with no external investment committee disclosed.

Norcliffe exclusively executes direct, single-company EIS and SEIS rounds. There is no evidence from the firm's website or public disclosures of the firm committing capital to external venture funds, fund-of-funds structures, or secondary transactions.

The firm's published mandate limits investments to the MedTech and BioTech sectors, and the disclosed portfolio contains only UK life-science companies. While not explicitly stated as avoided, technology, real estate, fintech, and other sectors outside life sciences are absent from all disclosed holdings.